Performance evaluation of antimicrobial peptide ll-37 and hepcidin and β-defensin-2 secreted by mesenchymal stem cells.
Esfandiyari. Reza R; Halabian. Raheleh R; Behzadi. Elham E; Sedighian. Hamid H; Jafari. Ramezan R; Imani Fooladi. Abbas Ali AA
Key Findings
- Mesenchymal stem cells can secrete antimicrobial peptides like LL‑37, hepcidin, and β‑defensin‑2 when exposed to bacteria.
- These peptides kill microbes mainly by disrupting their cell membrane integrity.
- The review highlights the potential of these naturally produced peptides as future therapeutic agents against infections.
Practical Outcomes
- For now, the information is mostly theoretical and doesn’t translate into actionable protocols for self‑experimentation or supplementation. More concrete research and safety data would be needed before biohackers could consider using these peptides in any practical way.
Summary
This paper reviews how certain immune‑boosting proteins (LL‑37, hepcidin and β‑defensin‑2) are naturally made by stem cells and can kill bacteria by messing with their cell membranes. It explains the basic ways these peptides work and why scientists think they could become new infection‑fighting drugs, but it doesn’t give any real‑world dosing or treatment tips.
Abstract
Peptides are secreted by different cell types and are trendy therapeutic agents that have attracted attention for the treatment of several diseases such as infections. Antimicrobial peptides exert various mechanisms such as changing cell membrane permeability which leads to inhibition or death of bacterial cells. mesenchymal stem cells (MSCs) are key to produce antimicrobial peptides and to inhibit the growth of pathogens. These cells have been shown to be capable of producing antimicrobial peptides upon exposure to different bacteria. As a result, antimicrobial peptides can be considered as novel agents for the treatment of infectious diseases. The purpose of this review was to investigate the targets and mechanisms of antimicrobial peptides secreted by MSCs.
Study Information
pubmed
2019
2019-10-23T00:00:00.000Z
10.1016/j.heliyon.2019.e02652
33
49